Drug Trial Radar · NCT06159725
A Study To Evaluate The Safety Of CMTX-101 In People With Cystic Fibrosis
Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
43
Actual
Start
Jun 24, 2024
Primary completion
Nov 14, 2025
Study completion Nov 14, 2025
Sponsor
- Lead sponsor
- Clarametyx Biosciences, Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 7, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
CMTX-101 is a bacterial biofilm disrupting monoclonal antibody being developed as an adjunctive therapy to standard of care antibiotics. The goal of this clinical trial is to assess the safety and tolerability of CMTX-101 in people with cystic fibrosis (pwCF). The main questions the study aims to answer are: * Are single doses of CMTX-101 IV infusion safe and tolerated * What is the pharmacokinetic (PK) profile of single doses of CMTX-101 * Do single doses of CMTX-101 induce development of anti-drug antibodies (ADA) and neutralizing antibodies (Nabs)
Conditions
- Persistent Infection
- Cystic Fibrosis
Interventions
CMTX-101Drug
CMTX-101 is a humanized monoclonal antibody administered as a single IV infusion over approximately 60 minutes.
PlaceboDrug
Placebo is normal saline administered as a single IV infusion over approximately 60 minutes.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number and % of participants experiencing adverse events following a single IV infusion of CMTX-101Time frame: Day 1 to Day 28
- Number and % of participants experiencing serious adverse events following a single IV infusion of CMTX-101Time frame: Day 1 to Day 28
Locations
23 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama, Birmingham
Birmingham, Alabama
Stanford University
Palo Alto, California
University of California, San Francisco
San Franciso, California
National Jewish Health
Denver, Colorado
Central Florida Pulmonary Group, PA
Orlando, Florida
St Luke's Sleep Medicine and Research Center
Boise, Idaho
Cystic Fibrosis Institute
Northfield, Illinois
University of Kansas
Kansas City, Kansas
Johns Hopkins University
Baltimore, Maryland
Boston Children's Hospital
Boston, Massachusetts
University of Michigan
Ann Arbor, Michigan
New York Medical College
Hawthorne, New York
Lenox Hill Hospital
New York, New York
Rainbow Babies and Children's Hospital/University Hospitals Cleveland Medical Center
Cleveland, Ohio
Nationwide Children's Hospital
Columbus, Ohio
PennState Health
Hershey, Pennsylvania
University of Pennsylvania
Philadelphia, Pennsylvania
UPMC Children's Hospital of Pittsburgh
Pittsburgh, Pennsylvania
Medical University of South Carolina
Charleston, South Carolina
Vanderbilt University
Nashville, Tennessee
University of Utah
Salt Lake City, Utah
Virginia Commonwealth University
Richmond, Virginia
Seattle Children's Hospital
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.